Entitled “International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma,” the peer-reviewed article, published online on ...

Results of a small study presented at the 66th American Society of Hematology Annual Meeting & Exposition suggest combining the bispecific elranatamab with the proteasome inhibitor carfilzomib can ...

The analysis of 11,427 Veterans Administration (VA) hospital patients with multiple myeloma (MM) reveals that lymphopenia affects 53% of patients at diagnosis. The median overall survival was 2.7 ...

Explore the transformative potential of bispecific antibodies in multiple myeloma, offering hope for improved patient outcomes and possible cures. In this episode, experts discuss how bispecific ...

Please provide your email address to receive an email when new articles are posted on . Lymphopenia at diagnosis or during follow-up can predict OS among patients with multiple myeloma. Researchers ...